Idenix Pharmaceuticals , Inc. ( IDIX ) Bank of America Merrill Lynch Health Care Conference Call ..... http://seekingalpha.com/article/1438651- idenix - pharmaceuticals -ceo-presents-at-bank-of-america-merrill
assumption that through sofosbuvir, Gilead Sciences ( GILD ) will dominate the entire HCV market, leaving Achillion, Idenix ( IDIX ), and other HCV players behind. However, while Gilead is likely to claim a large portion of the global HCV market, the market
Idenix Pharmaceuticals Inc ( IDIX ) Idenix Provides Update on Patent Interference March 25 ..... href='http://seekingalpha.com/article/1298971- idenix - pharmaceuticals -ceo-presents-idenix-provides-update-on-patent
Idenix Pharmaceuticals ( IDIX -12.6% ) slips back near its lows for the day, after the USPTO decided against it late Friday in the first phase of a two
After-hours top gainers, as of 5:15 p.m.: SFD +6% . REGI +6% . GTI +4% . FIVE +4% . KWK +4% . After-hours top losers: IDIX -10% . TTS -6% . SVU -4% . MTG -3% . ARNA -2% . 1 comment!
Idenix Pharmaceuticals Inc. ( IDIX ) Barclays Global Healthcare Conference Transcript March ..... Barclays. With us today here the next presenting company is Idenix Pharmaceuticals , and then I’m very pleased to introduce David Standring
Idenix Pharmaceuticals ( IDIX ): Q4 EPS of -$0.17 in-line. Revenue of $327K misses by $410M . ( PR ) Post your comment!
Idenix Pharmaceuticals , Inc. ( IDIX ) Update on IDX184 and IDX19368 Development Programs Conference Call February ..... http://seekingalpha.com/article/1158921- idenix - pharmaceuticals -ceo-presents-at-update-on-idx184-and-idx19368
After-hours top gainers, as of 5:15 p.m.: JNY +5% . EDMC +5% . BRKS +5% . MM +5% . GFF +4% . After-hours top losers: PC -10% . IDIX -7% . RTEC -6% . YUM -6% . BIDU -5% . Post your comment!
By Rx Stocks : Biotechnology companies, with new drugs, often trade at a high multiple (PE ratio). The current PE ratio for Vertex ( VRTX ) is near 80. Sometimes the growth rate justifies it. Admittedly, initial growth of Vertex' revenue was spectacular, as judged by year over year revenue growth.